Abstract
Renal cell carcinoma (RCC) remains a biologically heterogeneous malignancy with evolving therapeutic paradigms. Over the past two decades, advances in systemic therapies, surgical techniques, and local treatments have improved outcomes, yet challenges remain in predicting outcomes, tailoring treatment to risk, and treatment integration. This Special Collection, Renal Cell Carcinoma-From Genetics to Oncological and Surgical Treatments: New Insights, highlights recent innovations across these domains. Contributions include validation of prognostic tools such as the G8 geriatric screening and GRANT scores, exploration of stereotactic body radiotherapy for oligometastatic disease, and the emerging role of exosomes as biomarkers and therapeutic vehicles. Together, these findings underscore the importance of integrating molecular profiling, real-world data, and technological advances to guide personalized RCC management, with the ultimate aim of improving survival while preserving quality of life.